These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28550191)

  • 1. The level of deletion 17p and bi-allelic inactivation of
    Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
    Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
    Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
    Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
    Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
    Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells.
    Soenen V; Preudhomme C; Roumier C; Laï JL; Lepelley P; Facon T; Pagniez D; Fenaux P
    Leukemia; 1998 Feb; 12(2):238-41. PubMed ID: 9519788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
    Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
    Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
    Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
    Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
    Peterson JF; Rowsey RA; Marcou CA; Pearce KE; Williamson CM; Frederick LA; Greipp PT; Ketterling RP; Kumar S; Viswanatha DS; Polley MY; Fink JM; Reichard KK; Van Dyke DL; Baughn LB
    Blood Cancer J; 2019 Feb; 9(3):20. PubMed ID: 30783078
    [No Abstract]   [Full Text] [Related]  

  • 10. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of TP53 mutation in myeloma.
    Chng WJ; Price-Troska T; Gonzalez-Paz N; Van Wier S; Jacobus S; Blood E; Henderson K; Oken M; Van Ness B; Greipp P; Rajkumar SV; Fonseca R
    Leukemia; 2007 Mar; 21(3):582-4. PubMed ID: 17215851
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatic extramedullary disease in multiple myeloma with 17p deletion.
    Ise M; Tsujimura H; Sakai C; Kumagai K
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e165-8. PubMed ID: 25018063
    [No Abstract]   [Full Text] [Related]  

  • 13. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer.
    Khine K; Smith DR; Goh HS
    Cancer; 1994 Jan; 73(1):28-35. PubMed ID: 8275434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation.
    Vaxman I; Visram A; Kapoor P; Kumar S; Dispenzieri A; Buadi F; Dingli D; Muchtar E; Gonsalves W; Rajkumar V; Kourelis T; Warsame R; Lacy M; Gertz MA
    Am J Hematol; 2021 Jan; 96(1):E35-E38. PubMed ID: 33068019
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis, Biology, and Targeting of
    Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
    Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
    Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
    Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.
    Blount PL; Ramel S; Raskind WH; Haggitt RC; Sanchez CA; Dean PJ; Rabinovitch PS; Reid BJ
    Cancer Res; 1991 Oct; 51(20):5482-6. PubMed ID: 1680552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
    Stöcklein H; Smardova J; Macak J; Katzenberger T; Höller S; Wessendorf S; Hutter G; Dreyling M; Haralambieva E; Mäder U; Müller-Hermelink HK; Rosenwald A; Ott G; Kalla J
    Oncogene; 2008 Apr; 27(18):2613-25. PubMed ID: 17982487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.